Pfizer, Valneva stand to gain from Sanofi's C. diff vaccine flop: report

Pfizer, Valneva stand to gain from Sanofi's C. diff vaccine flop: report

Pfizer's and Valneva's vaccines could one day compete in a $1 billion C. diff market.

Sanofi recently canned the development of its Clostridium difficile vaccine, dashing its hopes of winning a license for the first shot against the bacterium that's often found in healthcare facilities. But the drugmaker's loss is a win for Pfizer and Valneva, which boast their own late-stage candidates aiming for a share of a market potentially worth $1 billion.